|
|
Vaccine Detail
|
melanoma helper peptide vaccine |
| Vaccine Information |
- Vaccine Name: melanoma helper peptide vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: 12 melanoma peptides restricted by Class I MHC (12MP) and 6 melanoma helper peptides (6HP) (NCT00071981)
- Immunization Route: subcutaneous and intradermal
- Description: This is a multivalent vaccine consisting of peptides derived from melanoma-associated antigens and an adjuvant peptide derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing melanoma-associated antigens, resulting in tumor cell lysis. (NCIT_C38700) Vaccines made from peptides may make the body build an immune response to kill tumor cells. Vaccines using melanoma peptides from cytotoxic T cells and helper T cells could work in treating patients with metastatic melanoma. This vaccine contains 12 melanoma peptides restricted by Human Leukocyte Antigen (HLA)-A1, -A2, or -A3 and 6 melanoma helper peptides restricted by HLA-DR molecules emulsified with sargramostim (Granulocyte-macrophage colony-stimulating factor, GM-CSF) and Montanide ISA-51 or Montanide ISA-51 VG (ISA-51). (NCT00071981)
|
| Host Response |
|
|
| References |
NCIT_C38700: Melanoma Helper Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38700]
NCT00071981: [https://clinicaltrials.gov/ct2/show/NCT00071981]
|
|
